

August 08, 2025

To,

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra-Kurla Complex,  
Bandra (East),  
Mumbai - 400 051

**Scrip code: 512529**

**Scrip code: SEQUENT**

**Subject: Press Release & Investor Presentation for Q1 FY 2025-26**

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Press Release and Investor Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025.

This is for your information and appropriate dissemination.

Thanking you,

**Yours faithfully,**

**For Sequent Scientific Limited**

**Yoshita Vora**

**Company Secretary & Compliance Officer**

**Encl: A/a**

**SeQuent Scientific Limited**

**Registered Office:** 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

**Office:** 301, 3<sup>rd</sup> Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

**Tel No.:** +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

**Website:** <http://www.sequent.in> | **Email Id:** [investorrelations@sequent.in](mailto:investorrelations@sequent.in)

## Strong Growth Momentum Continues

### Q1 FY26 – Revenues at ₹ 4,414 Million, up by 13.1%

### EBITDA at ₹ 602 Million, up by 24.7%

### PAT at ₹ 176 Mn, up by 93.7%

SeQuent Scientific Limited (SeQuent) today announced its financial results for the quarter ending June 30, 2025

**Mumbai, Aug 08, 2025**

#### Consolidated Financial Highlights

₹ in millions

	Q1FY26	Q1FY25	Growth %
<b>Revenues</b>	<b>4,414</b>	<b>3,902</b>	<b>13.1%</b>
<b>Adj EBITDA*</b>	<b>602</b>	<b>483</b>	<b>24.7%</b>
<b>Adj. EBITDA Margins</b>	<b>13.6%</b>	<b>12.4%</b>	<b>120 bps</b>
<b>PAT</b>	<b>176</b>	<b>91</b>	<b>93.7%</b>

\*Adjustment EBITDA Adjustment for ESOP and foreign currency fluctuation

#### Detailed presentation on the performance forms part of this press release

Commenting on the Company’s performance, **Rajaram Narayanan, Managing Director** stated “This quarter reinforces the momentum that we have built over the last 18 months, as we continue to deliver higher growth and profitability across all parts of the business. This has come on the back of initiatives in the areas relating to superior product mix, new launches and improved operational efficiency. Our proposed merger with Viyash Life Sciences is proceeding on plan and we expect all regulatory requirements to be completed in the next few months. We have commenced working on the Sequent 3.0 roadmap to leverage the synergies resulting from the merger and accelerate profitable revenue growth.”

## Earnings Call with Investors

---

The Company will conduct an Earnings call at **9:00 AM IST on August 11, 2025** where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**

## About SeQuent Scientific Limited

---

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has seven manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India's first and only USFDA approved facility for veterinary APIs.

## For details, feel free to contact

---

### Yoshita Vora

Company Secretary, Tel: +91 22 4111 4717  
investorrelations@sequent.in

### Abhishek Singhal

Investor Relations Consultants  
abhishek@arunya.co.in

### Registered Office

3rd Floor, Srivalli's Corporate,  
Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills,  
Shaikpet, Hyderabad-500033, Telangana  
CIN: L99999TS1985PLC196357  
BSE Code: 512529 I NSE: SEQUENT  
ISIN: INE807F01027 I REUTERS: EQU.BO  
Website: [www.sequent.in](http://www.sequent.in)

*Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. SeQuent Scientific Ltd. will not be responsible in any way for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstance*



# INVESTOR PRESENTATION

---

## Q1 FY26

SEQUENT SCIENTIFIC LIMITED

08<sup>th</sup> Aug 2025

## Steadfast commitment to improvement in business fundamentals

“This quarter reinforces the momentum that we have built over the last 18 months, as we continue to deliver higher growth and profitability across all parts of the business. This has come on the back of initiatives in the areas relating to superior product mix, new launches and improved operational efficiency. Our proposed merger with Viyash Life Sciences is proceeding on plan and we expect all regulatory requirements to be completed in the next few months. We have commenced working on the Sequent 3.0 roadmap to leverage the synergies resulting from the merger and accelerate profitable revenue growth.”

**Rajaram Narayanan**

**Managing Director and CEO**

---

## SeQuent & Viyash : Proforma Q1FY26 Combined Performance

# Q1 FY26 Performance Highlights

All values in ₹ Mn


## Revenues



## EBITDA (pre- ESOP)<sup>1</sup>



## EBITDA margin



## Net Debt to LTM Adj. EBITDA<sup>1</sup>



---

SeQuent

Q1FY26 Performance Update



# Strong profitable business growth continues in Q1FY26

All values in ₹ Mn


## Revenues



## Adj. EBITDA\*



## Adj. EBITDA\* margin



## PAT



\* EBITDA Adjustment for ESOP and foreign currency fluctuation

# Broad based revenue growth in Q1FY26

All values in ₹ Mn

Revenue Distribution	Q1 FY26	Q1 FY25	YoY Gr%	Q4 FY25	QnQ Gr%
<b>Formulations</b>	<b>3,383</b>	<b>3,002</b>	<b>13%</b>	<b>3,057</b>	<b>11%</b>
Europe	1,640	1,571	4%	1,365	20%
Emerging Markets	1,480	1,187	25%	1,429	4%
India	263	244	8%	263	0%
<b>APIs</b>	<b>1,054</b>	<b>924</b>	<b>14%</b>	<b>869</b>	<b>21%</b>
Other Sales	15	41	(64%)	25	(43%)
<b>Global Sales</b>	<b>4,451</b>	<b>3,967</b>	<b>12%</b>	<b>3,951</b>	<b>13%</b>
One Offs #	(56)	(86)			
Adjustment* - Ind AS 29*	19	21		66	
<b>Reported Sales</b>	<b>4,414</b>	<b>3,902</b>	<b>13%</b>	<b>4,017</b>	<b>10%</b>

\*Adjustment on account of hyperinflation in Turkey as per Ind AS 29

# Provision for customer claim on shipments in prior years

# SeQuent: Q1FY26 Business Performance

All values in ₹ Mn

## Formulations


- ✓ **Europe:** Successful completion of Spanish GMP Audit || Regulatory approval received for new launches
- ✓ **Emerging Market:** Received EU approval for two product's manufacturing site change from Germany to Turkey
- ✓ **LATAM:** Expanded sales team in Mexico
- ✓ **India:** Completed onboarding of additional field team as part of Udaan 2.0



**1,000+**  
FDFs



**90+**  
Countries



**5**  
Manufacturing  
Facilities

## API

- ✓ Strong business momentum, 14% YoY growth
- ✓ Received a CEP approval during the quarter
- ✓ Completed successful audits by 2 key customers with no critical observations
- ✓ Increased interest in Albendazole post WHO Prequalification



**35**  
APIs



**50+**  
Countries



**2**  
Manufacturing  
facilities

# Consolidated Financials

All values in ₹ Mn

Particulars	Q1 FY26	Q1 FY25	Grw YoY %	Q4 FY25	Grw QnQ %
Revenue from Operations	4,414	3,902	13.1%	4,017	9.9%
Material Consumption	(2,345)	(2,143)		(1,997)	
<b>Gross Margin</b>	<b>2,069</b>	<b>1,759</b>	<b>17.6%</b>	<b>2,020</b>	<b>2.4%</b>
%	46.9%	45.1%		50.3%	
Employee Benefit Expenses	(677)	(579)	16.9%	(653)	3.7%
Operating Expenses	(789)	(697)	13.3%	(797)	-0.9%
<b>EBITDA (pre-ESOP)</b>	<b>602</b>	<b>483</b>	<b>24.7%</b>	<b>569</b>	<b>5.7%</b>
%	13.6%	12.4%		14.2%	
ESOP cost	(114)	(41)		(114)	
<b>EBITDA</b>	<b>489</b>	<b>442</b>	<b>10.6%</b>	<b>456</b>	<b>7.3%</b>
%	11.1%	11.3%		11.3%	
Exceptional Items	(13)	-		(3)	
IndAS 29 Adjustment	37	(8)		6	
Exchange Gain / (Loss)	(4)	(14)		0	
Other Income	39	27		16	
Finance Cost	(142)	(164)		(151)	
Depreciation	(151)	(162)		(161)	
<b>Earnings Before Tax</b>	<b>255</b>	<b>120</b>	<b>112.6%</b>	<b>163</b>	<b>56.8%</b>
Taxes	(80)	(29)		(59)	
<b>Earnings After Tax</b>	<b>176</b>	<b>91</b>	<b>93.7%</b>	<b>103</b>	<b>69.7%</b>
Minority Interest	33	25		11	
<b>Earnings after Minority Interest</b>	<b>143</b>	<b>65</b>	<b>119%</b>	<b>93</b>	<b>54.1%</b>

## Key Notes

**+13% YoY in Q1 sales with +178 bps gross margin improvement**

**Employee Benefit & Operating Expenses:** One-time hiring and expansion in key markets

**ESOP:** New shares allotted in FY25

**Exceptional Item:** ~₹13 Mn Merger related expense

**Finance Cost:** Gradual repayment of high-cost debt and lower borrowing rates driven by central bank policy easing



---

# Viyash: Business Update

# Viyash: Q1 FY26 – Strong profitability and continued improvement in margins




## Revenues



## Adj. EBITDA<sup>1</sup>




## EBITDA margin



## Net Debt to LTM Adj. EBITDA<sup>1</sup>



# Key updates from Q1 FY26



## Facility Inspections

- ✓ **5** Regulatory Audits
- ✓ **34** Customer audits
- ✓ **1** US FDA EIR



## Products Filed

- ✓ **12 APIs** – KR DMF (1), EDMF (2) Saudi Arabia (2), CN DMF (1), Others (6)
- ✓ **5 FDFs** (US)



## Regulatory Approvals

- ✓ **5 APIs:** USDMF (1), CEPs (3), EDMF(1)
- ✓ **1 FDF**



## Validations Completed

- ✓ **3 APIs**



## Launches

- ✓ **2 FDFs** (US)
- ✓ **2 APIs**



## R&D Pipeline

- ✓ **16+** Products

# Financial performance

All values in ₹ Mn



Particulars	Q1	Q1	YoY %	Q4	QoQ %	FY25	FY24	YoY %
	FY26	FY25		FY25				
Revenue from Operations	3,527	3,400	3.7%	3,708	-4.9%	14,580	13,110	11.2%
Material Consumption	(1,480)	(1,580)	-6.3%	(1,652)	-10.4%	(6,608)	(6,142)	7.6%
<b>Gross Profit</b>	<b>2,047</b>	<b>1,820</b>	<b>12.4%</b>	<b>2,056</b>	<b>-0.5%</b>	<b>7,971</b>	<b>6,968</b>	<b>14.4%</b>
%	58.0%	53.5%		55.4%		54.7%	53.2%	
Operating Expenses	(1,369)	(1,249)	9.6%	(1,405)	-2.6%	(5,490)	(5,332)	3.0%
Foreign Exchange Gain / (Loss)	10	9		3		65	34	
<b>Adj. EBITDA<sup>1</sup></b>	<b>688</b>	<b>580</b>	<b>18.6%</b>	<b>653</b>	<b>5.2%</b>	<b>2,546</b>	<b>1,671</b>	<b>52.4%</b>
%	19.5%	17.1%		17.6%		17.5%	12.7%	



---

# Merger Update

# Q1FY26: Combined business performance

Q1 FY26 (For the quarter)	Viyash	+	Sequent Proven Ability In Life Science	=	Combined	YoY Growth % (Combined)
Revenue (INR Mn)	3,527		4,414		7,941	8.7%
EBITDA <sup>1</sup> (INR Mn)	688		602		1,290	21.4%
EBITDA Margin %	19.5%		13.6%		16.2%	+169bps
Net Debt to LTM EBITDA	0.3x		1.9x		0.6x	

Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs

Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

# Combined P&L – Snapshot

Particulars	Viyash		SeQuent		Combined	
	FY25	Q1FY26	FY25	Q1FY26	FY25	Q1FY26
Revenue from Operations	14,580	3,527	15,514	4,414	30,094	7,941
Material Consumption	(6,608)	(1,480)	(8,119)	(2,345)	(14,727)	(3,825)
<b>Gross Margin</b>	<b>7,971</b>	<b>2,047</b>	<b>7,395</b>	<b>2,069</b>	<b>15,367</b>	<b>4,116</b>
%	54.7%	58.0%	47.7%	46.9%	51.1%	51.8%
Operating Expenses	(5,490)	(1,369)	(5,402)	(1,467)	(10,892)	(2,836)
Operating Exchange Gain / (Loss)	65	10	-	-	65	10
<b>Adjusted EBITDA</b>	<b>2,546</b>	<b>688</b>	<b>1,993</b>	<b>602</b>	<b>4,539</b>	<b>1,290</b>
%	17.5%	19.5%	12.8%	13.6%	15.1%	16.2%
ESOP cost	(82)	(16)	(324)	(114)	(406)	(130)
Exceptional Items <sup>1</sup>	(979)	-	(50)	(13)	(1,029)	(13)
Ind AS 29 Adjustment	-	-	29	37	29	37
Exchange Gain / (Loss)	-	-	(80)	(4)	(80)	(4)
Other Income	182	23	147	39	329	62
Finance Cost	(256)	(63)	(608)	(142)	(864)	(205)
D&A	(720)	(164)	(589)	(134)	(1,309)	(298)
Amortization of Acquisition Intangibles	(1,003)	(241)	(76)	(17)	(1,079)	(258)
<b>Profit Before Tax</b>	<b>(311)</b>	<b>228</b>	<b>443</b>	<b>255</b>	<b>132</b>	<b>483</b>
Taxes	146	(35)	(120)	(80)	26	(115)
<b>Profit After Tax</b>	<b>(165)</b>	<b>193</b>	<b>322</b>	<b>176</b>	<b>157</b>	<b>369</b>
<b>Adjusted PAT<sup>2</sup></b>	<b>1,296</b>	<b>370</b>	<b>429</b>	<b>197</b>	<b>1,725</b>	<b>567</b>

## Key Notes :

- ESOP cost, Exceptional items and amortization of acquisition intangibles are non-cash or non-recurring accounting items that pertain to prior period events:
- Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses and provision for a contractual one-time bonus payable at Viyash
  - Amortization of acquisition intangibles in Viyash is on account of intangibles created during acquisitions done in FY22. This accounting amortization will continue till FY27

1. Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses (Viyash) and one-time contractual bonus payable to Viyash management (Viyash)

2. PAT adjusted for Amortization of acquisition intangibles and Exceptional Items (net of tax)

Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

# Merger – Process Update

## Merger process status update

- CCI approval and Stock Exchange clearance received
- Filing of Application with NCLT completed
- NCLT directions received on July 23, 2025, to conduct equity shareholders and unsecured trade creditors meeting of the Company on August 30, 2025.
- **Expected timelines for the completion of the merger process as indicated to be 12-15 months (from merger announcement in September 2024).**
- **The process is well on track as per estimated timelines**



# Synergy Update

## Synergy Planning Process on Track


- ✓ *CCI approval and Stock exchange approval received*
- ✓ *Integration planning workshops kicked off*
- ✓ *Granular synergy action plan & estimated value being worked upon*


4 Core synergy areas identified		Synergy Realization Timeline (Months)			
Area	Key Ideation Action Items	Till Merger Approval	0-6	6-12	12+
R&D	<ul style="list-style-type: none"> <li>R&amp;D teams to be co-located; to work collaboratively on NPD &amp; cost improvement</li> <li>QA &amp; Testing to be moved on-site from 3<sup>rd</sup> party location</li> </ul>				
Manufacturing	<ul style="list-style-type: none"> <li>Utilize available low-cost capacity through the group; action plan created</li> <li>Procurement synergies identified</li> </ul>				
Sales	<ul style="list-style-type: none"> <li>Leverage key relationships of both companies; outreach &amp; discussion plan prepared</li> </ul>				
Others	<ul style="list-style-type: none"> <li>Assess shared administrative &amp; support functions</li> </ul>				
In advanced stages		We are here			

***For details, feel free to contact:***

**Yoshita Vora**


**Company Secretary**

 +91 22 4111 4777

 investorrelations@sequent.in

**Abhishek Singhal**

**Investor Relations Consultant**

 abhishek@arunya.co.in

***Registered Office: 3<sup>rd</sup> Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39,  
Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana***

**Websites: [www.sequent.in](http://www.sequent.in), [www.alivira.co](http://www.alivira.co) | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: SEQUENT**

**ISIN: INE807F01027**

*Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*

---

Thank You